David Beauvais

David Beauvais

Auto-generated profile, based on publicly available information

David Beauvais

Hematology Department, CHU Lille, Lille, France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
EBEmmanuel Bachy
Emmanuel Bachy
SGSteven Le Gouill
Steven Le Gouill
RBRoberta Di Blasi
Roberta Di Blasi
PSPierre Sesques
Pierre Sesques
GMGuillaume Manson
Guillaume Manson
FMFranck Morschhauser
Franck Morschhauser
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). In this study, we analyzed the outcome of 809 patients with R/R DLBCL after two or more previous lines of treatment who had a commercial chimeric antigen receptor (CAR) T cells order for axi-cel or tisa-cel and were registered in the retrospective French DESCAR-T registry study (NCT04328298). After 1:1 propensity score matching (n = 418), the best overall response rate/complete response rate (ORR/CRR) was 80%/60% versus 66%/42% for patients treated with axi-cel compared to tisa-cel, respectively (P < 0.001 for both ORR and CRR comparisons). After a median follow-up of 11.7 months, the 1-year progression-free survival was 46.6% for axi-cel and 33.2% for tisa-cel (hazard ratio (HR) = 0.61; 95% confidence interval (CI), 0.46–0.79; P = 0.0003). Overall survival (OS) was also significantly improved after axi-cel infusion compared to after tisa-cel infusion (1-year OS 63.5% versus 48.8%; HR = 0.63; 95% CI, 0.45–0.88; P = 0.0072). Similar findings were observed using the inverse probability of treatment weighting statistical approach. Grade 1–2 cytokine release syndrome was significantly more frequent with axi-cel than with tisa-cel, but no significant difference was observed for grade ≥3. Regarding immune effector cell-associated neurotoxicity syndrome (ICANS), both grade 1–2 and grade ≥3 ICANS were significantly more frequent with axi-cel than with tisa-cel. In conclusion, our matched comparison study supports a higher efficacy and also a higher toxicity of axi-cel compared to tisa-cel in the third or more treatment line for R/R DLBCL.

15 December 2022 in Blood
Verified
Journal Article
Open access
PDF file
RBRoberta Di Blasi
Roberta Di Blasi
SGSteven Le Gouill
Steven Le Gouill
EBEmmanuel Bachy
Emmanuel Bachy
GCGuillaume Cartron
Guillaume Cartron
DBDavid Beauvais
David Beauvais
CTCatherine Thieblemont
Catherine Thieblemont
Anti-CD19 chimeric antigen receptor (CAR) T-cells represent a major advance in the treatment of relapsed/refractory aggressive B-cell lymphomas. However, a significant number of patients experience failure. Among 550 patients registered in the French registry DESCAR-T, 238 (43.3%) experienced progression/relapse, with a median follow-up of 7.9 months. At registration, 57.0% of patients presented an age-adjusted International Prognostic Index of 2 to 3, 18.9% had Eastern Cooperative Oncology Group performance status ≥2, 57.1% received >3 lines of treatment prior to receiving CAR T-cells, and 87.8% received bridging therapy. At infusion, 66% of patients presented progressive disease, and 38.9% had high lactate dehydrogenase (LDH). Failure after CAR T-cell treatment occurred after a median of 2.7 months (range: 0.2-21.5). Fifty-four patients (22.7%) presented very early failure (day [D] 0-D30); 102 (42.9%) had early failure (D31-D90), and 82 (34.5%) had late (>D90) failure. After failure, 154 patients (64%) received salvage treatment: 38.3% received lenalidomide, 7.1% bispecific antibodies, 21.4% targeted treatment, 11% radiotherapy, and 20% immunochemotherapy with various regimens. Median progression-free survival was 2.8 months, and median overall survival (OS) was 5.2 months. Median OS for patients failing during D0-D30 vs after D30 was 1.7 vs 3.0 months, respectively (P = .0001). Overall, 47.9% of patients were alive at 6 months, but only 18.9% were alive after very early failure. In multivariate analysis, predictors of OS were high LDH at infusion, time to CAR-T failure <D30, and high C-reactive protein at infusion. This multicentric analysis confirms the poor outcome of patients relapsing after CAR T-cell treatment, highlighting the need for further strategies dedicated to this population.

25 August 2020 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Closed access
PDF file
JDJulie Demaret
Julie Demaret
PVPauline Varlet
Pauline Varlet
JTJacques Trauet
Jacques Trauet
DBDavid Beauvais
David Beauvais
AGAurélien Grossemy
Aurélien Grossemy
MLMyriam Labalette
Myriam Labalette

12 June 2014 in Clinical Cancer Research
Verified
Journal Article
Closed access
GFGuillemette Fouquet
Guillemette Fouquet
SGStéphanie Guidez
Stéphanie Guidez
CHCharles Herbaux
Charles Herbaux
ZWZoé Van de Wyngaert
Zoé Van de Wyngaert
SBSarah Bonnet
Sarah Bonnet
XLXavier Leleu
Xavier Leleu
Purpose: Solitary plasmacytoma (SP) is a localized proliferation of monoclonal plasma cells in either bone or soft tissue, without evidence of multiple myeloma (MM), and whose prognosis is marked by a high risk of transformation to MM. Experimental Design: We studied the impact of FDG-PET/CT (2[18F]fluoro-2-deoxy-D-glucose positron emission tomography–computed tomography) on the risk of transformation of SP to overt MM among other markers in a series of 43 patients diagnosed with SP. Results: Median age was 57.5 years; 48% of patients had an abnormal involved serum-free light chain (sFLC) value, and 64% had an abnormal sFLC ratio at diagnosis. Thirty-three percent had two or more hypermetabolic lesions on initial PET/CT, and 20% had two or more focal lesions on initial MRI. With a median follow-up of 50 months, 14 patients transformed to MM with a median time (TTMM) of 71 months. The risk factors that significantly shortened TTMM at diagnosis were two or more hypermetabolic lesions on PET/CT, abnormal sFLC ratio and involved sFLC, and to a lesser extent at completion of treatment, absence of normalized involved sFLC and PET/CT or MRI. In a multivariate analysis, abnormal initial involved sFLC [OR = 10; 95% confidence interval (CI), 1–87; P = 0.008] and PET/CT (OR = 5; 95% CI, 0–9; P = 0.032) independently shortened TTMM. Conclusions: An abnormal involved sFLC value and the presence of at least two hypermetabolic lesions on PET/CT at diagnosis of SP were the two predictors of early evolution to myeloma in our series. This data analysis will need confirmation in a larger study, and the study of these two risk factors may lead to a different management of patients with SP in the future. Clin Cancer Res; 20(12); 3254–60. ©2014 AACR.

11 December 2019 in Leukemia
Verified
Journal Article
Closed access
PDF file
Nicolas DuployezNicolas Duployez
Nicolas Duployez
LGLaure Goursaud
Laure Goursaud
LFLaurène Fenwarth
Laurène Fenwarth
CBClaire Bories
Claire Bories
AMAlice Marceau-Renaut
Alice Marceau-Renaut
CPClaude Preudhomme
Claude Preudhomme

5 August 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
NGNicolas Gazeau
Nicolas Gazeau
DBDavid Beauvais
David Beauvais
IYIbrahim Yakoub-Agha
Ibrahim Yakoub-Agha
SMSuman Mitra
Suman Mitra
TCTimothy B. Campbell
Timothy B. Campbell
SMSalomon Manier
Salomon Manier
The recent emergence of anti–B-cell maturation antigen (BCMA) therapies holds great promise in multiple myeloma (MM). These include chimeric antigen receptor (CAR) T cells, bispecific antibodies, and antibody-drug conjugates. Their development in clinical trials and further approval are changing the strategy for treating MM. Considering that a cure has not been reached, a central question in the coming years will be the possibility of using these therapies sequentially. Here, we report 2 cases of the serial use of anti-BCMA therapies with parallel monitoring of BCMA expression and anti-CAR antibodies. We further discuss recent data from clinical studies that have informed us about the different mechanisms of resistance to anti-BCMA therapies, including antigen escape, BCMA shedding, anti-drug antibodies, T-cell exhaustion, and the emergence of an immunosuppressive microenvironment. This knowledge will be essential to help guide the strategy of serial treatments with anti-BCMA therapies.